AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04855526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/No CBD Marihuana
Description: high THC (65 mg THC) and no CBD (0 mg CBD)
Study NCT04855526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/High CBD Marihuana
Description: high THC (65 mg THC) and high CBD (50 mg CBD)
Study NCT06115772 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT05180942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium 40Mg Tab
Description: One tablet daily
Study NCT04234906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
Study NCT04234906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
Study NCT04234906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
Study NCT04234906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procainamide
Description: IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
Study NCT04855526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No THC/No CBD Marihuana
Description: no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
Study NCT05603702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Description: Participants will topically apply Sunscreen A at Visit 1.
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen B
Description: Participants will apply Sunscreen B at Visit 1.
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C
Description: Participants will apply Sunscreen C at Visit 1.
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen D
Description: Participants will apply Sunscreen D at Visit 1.
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen E
Description: Participants will apply Sunscreen E at Visit 1.
Study NCT05565625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen F
Description: Participants will apply Sunscreen F at Visit 1.
Study NCT05153096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-015
Description: NBL-015 by intravenous infusion
Study NCT05469659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Description: Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
Study NCT05469659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
Study NCT06266728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total30 for Astigmatism Contact Lenses
Description: Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
Study NCT05437120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT06363721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PerioPull™
Description: PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
Study NCT05073107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Dental Application, Dental Monitoring (DM)
Description: o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos.
Study NCT01996475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Study NCT05075811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ossium vBM-MSC
Description: Vertebral bone marrow derived mesenchymal stem cells
Study NCT05075811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT05580133 — intervention group
Intervention type: PROCEDURE
Intervention: anterior cruciate ligament reconstruction
Description: Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
Study NCT05462847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer acetate
Description: 8ml/kg Ringer acetate over 10 minutes
Study NCT05462847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: 8ml/kg Ringer acetate over 10 minutes
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg CVL-231 as IR formulation
Description: Tablets
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as slow-release MR formulation
Description: Capsules
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as medium release MR formulation
Description: Capsules
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 as fast release MR formulation
Description: Capsules
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 Target Release, Fasted
Description: Capsules
Study NCT05106309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg CVL-231 Target Release, Fed
Description: Capsules
Study NCT01411254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） Low Dose
Study NCT01411254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） High Dose
Study NCT01411254 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT04851587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person (or Remote) Intervention
Description: Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
Study NCT04649255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Embolic
Description: Lava Liquid Embolic System (LES)
Study NCT06080828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Posterior Tibial Nerve Stimulation
Description: 20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
Study NCT06080828 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Percutaneous Posterior Tibial Nerve Stimulation
Description: placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
Study NCT06080828 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home instructions
Description: they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
Study NCT06080828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home instructions
Description: they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
Study NCT06183723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of social-behavior model and eHealth
Description: The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects.
Study NCT05294055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 1.5-1.8g/m2, single dose
Study NCT05294055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
Study NCT05294055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 2
Description: Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
Study NCT05294055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim, day 5
Description: Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
Study NCT05183607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Nutrition Education
Description: 4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
Study NCT05453058 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
Description: Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice.
Study NCT04964427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
Study NCT04964427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
Study NCT04964427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
Study NCT04858477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual estimation of polyp size
Description: For each colonoscopy, a fellow will first visually estimate the polyp size
Study NCT04858477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Napoleon measurement of polyp size
Description: For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
Study NCT05311124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra Dermal Regeneration template (IDRT)
Description: Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
Study NCT05722119 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray GI
Description: Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
Study NCT05071950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control period
Description: * first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal
Study NCT05071950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-allulose period
Description: * \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose
Study NCT05227638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
Study NCT04170361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
Study NCT04170361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
Study NCT04170361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy+Incentive Spirometry
Description: All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
Study NCT04506008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-Hypo-fractionation Radiotherapy
Description: Five fractions of pre-operative radiation
Study NCT04506008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Surgery
Study NCT04506008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04506008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderately-Hypo-fractionation Radiotherapy
Description: 15 fractions of pre-operative radiation
Study NCT06073600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)
Description: The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
Study NCT06073600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)
Description: The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
Study NCT06073600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)
Description: The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
Study NCT06073600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)
Description: The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
Study NCT05705609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala art therapy
Description: A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.